GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zhejiang Nhu Co Ltd (SZSE:002001) » Definitions » Debt-to-EBITDA

Zhejiang Nhu Co (SZSE:002001) Debt-to-EBITDA : 2.12 (As of Mar. 2024)


View and export this data going back to 2004. Start your Free Trial

What is Zhejiang Nhu Co Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Zhejiang Nhu Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥2,075 Mil. Zhejiang Nhu Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥7,630 Mil. Zhejiang Nhu Co's annualized EBITDA for the quarter that ended in Mar. 2024 was ¥4,572 Mil. Zhejiang Nhu Co's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was 2.12.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Zhejiang Nhu Co's Debt-to-EBITDA or its related term are showing as below:

SZSE:002001' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.7   Med: 1.39   Max: 2.5
Current: 2.5

During the past 13 years, the highest Debt-to-EBITDA Ratio of Zhejiang Nhu Co was 2.50. The lowest was 0.70. And the median was 1.39.

SZSE:002001's Debt-to-EBITDA is ranked worse than
60.91% of 660 companies
in the Drug Manufacturers industry
Industry Median: 1.67 vs SZSE:002001: 2.50

Zhejiang Nhu Co Debt-to-EBITDA Historical Data

The historical data trend for Zhejiang Nhu Co's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zhejiang Nhu Co Debt-to-EBITDA Chart

Zhejiang Nhu Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.36 1.49 1.30 1.63 1.82

Zhejiang Nhu Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.22 2.32 3.17 2.92 2.12

Competitive Comparison of Zhejiang Nhu Co's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Zhejiang Nhu Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zhejiang Nhu Co's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Zhejiang Nhu Co's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Zhejiang Nhu Co's Debt-to-EBITDA falls into.



Zhejiang Nhu Co Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Zhejiang Nhu Co's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(2800.081 + 6826.883) / 5277.328
=1.82

Zhejiang Nhu Co's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(2075.281 + 7630.22) / 4572.284
=2.12

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.


Zhejiang Nhu Co  (SZSE:002001) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Zhejiang Nhu Co Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Zhejiang Nhu Co's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Zhejiang Nhu Co (SZSE:002001) Business Description

Traded in Other Exchanges
N/A
Address
No. 4 Jiangbei Road, Yulin Street, Xinchang County, Zhejiang Province, Shaoxing, CHN, 312500
Zhejiang Nhu Co Ltd is a China-based company engaged in the manufacture and sales of pharmaceuticals, health protection products, pharmaceutical intermediates, fragrances, food additives and feed additives. The company's active pharmaceutical ingredient products cover various areas such as Cardiovascular, Anti-AIDS, Anti-cancer and Anti-bacterial with key products such as Latamoxef Sodium, Flomoxef Sodium, Hydrochloride Moxifloxacin, Artemisinin series, Calcium Keto acid series, Vitamin A/E/D3 and coenzyme Q10 and others. The other business areas are Aroma chemicals, Polymers, and Nutrition. The organization markets its products in China and internationally.

Zhejiang Nhu Co (SZSE:002001) Headlines

No Headlines